Delivery Order SPE2DB20D1100-SPE2DB25FE0L8
- Not listed
- The Defense Logistics Agency awarded a $25,556.44 delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (quantity: 28 units) on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,334.66 to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28 count) on September 18, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price delivery order carries no set-aside designation and was competitively awarded. The pharmaceutical supply will be fulfilled from the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a $12.78K delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (28-count units) under a firm fixed-price contract. This non-set-aside award was issued on July 25, 2025, with an ultimate completion date of August 15, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for the supply of Attruby 356 mg tablets (28-count units). This firm fixed-price contract, issued on August 20, 2025, with completion targeted for September 11, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a $12,778.22 firm fixed price delivery order to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28-count packages) on April 24, 2025, with an ultimate completion date of May 15, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $25,556.44 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Attruby 356 mg tablets (28-count packaging). This is a firm fixed price, non-set-aside competitive delivery order with performance scheduled to conclude by September 30, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for the supply of Attruby 356 mg tablets (28-count package). This firm fixed-price, competitively awarded delivery order was executed on July 28, 2025, with an ultimate completion date of August 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 30, 2025, by the Defense Logistics Agency for the supply of ATTRUBY 356 mg tablets (28 count). The contract, valued at $12,778.22, carries a firm fixed price structure with an ultimate completion date of August 20, 2025. This is a non-set-aside competitive award, reflecting the vendor's demonstrated capability to meet federal pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Attruby 356 mg tablets (28-count units) with a ceiling value of $12,778.22. This firm fixed-price, non-set-aside delivery order is scheduled for completion by October 6, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0L8Delivery Order
The Defense Logistics Agency awarded a $19,134.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (28-count) with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal medical procurement needs. As a critical vendor within the Defense Health Agency supply chain, AmerisourceBergen Drug Corp leverages its prime IDC with DLA to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for military healthcare systems and other federal customers. The company's demonstrated capability to compete successfully across a range of delivery orders—from minimal transactions to orders exceeding $45,000—underscores its position as a key provider of both brand-name and generic medications, vaccines, and specialized medical supplies supporting the Department of Defense healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.1k | 8/13/25 |